Nektar says Phase 2b REZOLVE-AA trial posts new 6-month off-treatment rezpegaldesleukin data in severe alopecia areata
NKTR•Nektar said it will present new Phase 2b REZOLVE-AA data on six-month off-treatment rezpegaldesleukin in severe alopecia areata at EADV 2026 in Vienna. The company scheduled an investor webcast for Oct. 1, 2026, to discuss the results.
1. Alopecia areata data
Nektar said the presentation will cover follow-up after treatment stops, focusing on whether hair regrowth benefits persist. The data are slated for future presentation at EADV 2026 in Vienna.
2. Other EADV findings
Separate oral sessions will present atopic dermatitis maintenance findings on sustained symptom improvement with less frequent dosing. A late-breaking biomarker readout will detail early molecular changes consistent with drug activity.
3. Investor webcast
Nektar scheduled an investor webcast for Oct. 1, 2026, to discuss the off-treatment alopecia areata results.
